The S&P/ASX All Ordinaries Index (ASX: XAO) is slightly in the red on Friday, down 0.11%.
There are 500 companies within the ASX All Ords index.
We thought it might be interesting to see which ASX All Ords share delivered the best capital growth in FY24 and which one languished at the bottom of the pile.
The results are in.
Best ASX All Ords share of FY24 for growth
Clarity Pharmaceuticals Ltd (ASX: CU6)
ASX All Ords healthcare share Clarity Pharmaceuticals shot the lights out in FY24. The Clarity Pharmaceuticals share price soared by 674.29% over the 12 months.
Clarity is a clinical-stage radiopharmaceutical company. It's developing next-generation therapy and imaging products used for the diagnosis and treatment of cancer and other serious diseases.
The majority of the stock's impressive price ascension in FY24 began in April.
That's when the company announced that the first patient ever to be dosed with two cycles of 67Cu-SAR-bisPSMA at 8GBq had a complete response to treatment based on RECIST criteria.
That meant the patient had maintained undetectable levels of prostate cancer for almost six months.
In March, Clarity successfully completed an institutional capital raising of $110 million. It then ran a fully underwritten retail entitlement offer at $2.55 per share, which raised a further $10.8 million.
The funds will be used to continue radiopharmaceutical product development.
Last month, Clarity announced it had received a near-$10 million research and development tax incentive refund as part of the Australian Federal Government's R&D Tax Incentive program.
The Clarity Pharmaceuticals share price closed FY24 at $5.42.
Worst ASX All Ords share of FY24
Core Lithium Ltd (ASX: CXO)
The share price of ASX All Ords lithium share Core Lithium tanked by 90% in FY24.
Just a year ago on 30 June 2023, Core Lithium shares were worth 90 cents a piece. That was already a devastating 52% fall from their all-time record high of $1.875 on 13 November 2022.
On the final trading day of FY24, the Core Lithium share price closed at 9.35 cents. So, it's not surprising that the stock was at the bottom of the ASX All Ords index for FY24.
The biggest news out of the company in FY24 was the suspension of mining at its flagship Finniss Project in the Northern Territory in January.
The company did this to conserve capital while lithium prices continued to fall. Since then, Core Lithium has continued analysing exploration results and processing stockpiled ore.
In the latest quarterly update, Core Lithium told investors its cash balance had reduced from $124.8 million at the end of December to $80.4 million at the end of March.
However, the company said it intended to sell an inventory of lithium concentrate and fines in 4Q FY24. At the time of the announcement, it valued the inventory at $25 million.
